Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 13;37:149. doi: 10.1186/s13046-018-0831-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 6 — LINC01287 inhibition decreased tumor growth and invasion in vivo. a Compared with sh-ctrl cell-derived xenograft tumors, sh- LINC01287 cell-derived xenograft tumors grew more slowly, while anti-miR-298 treatment partly abolished this effect. b The mean weight of sh-LINC01287 cell-derived xenograft tumors was significantly lower than that of sh-ctrl cell-derived xenograft tumors, while anti-miR-298 treatment partly abolished this effect. c The knockdown of LINC01287 significantly decreased the percentage of Ki-67-positive cells in the tumors compared with the negative control group, while anti-miR-298 treatment partly abolished this effect. d The knockdown of LINC01287 decreased lung metastasis in vivo, while anti-miR-298 treatment partly abolished this effect